Literature DB >> 18408109

Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable.

David T Felson1, Bin Zhang, Jeffrey N Siegel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18408109      PMCID： PMC2758240          DOI： 10.1136/ard.2007.079632

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  18 in total

1.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Authors:  R N Maini; P C Taylor; J Szechinski; K Pavelka; J Bröll; G Balint; P Emery; F Raemen; J Petersen; J Smolen; D Thomson; T Kishimoto
Journal:  Arthritis Rheum       Date:  2006-09

2.  The BeSt way to treat early rheumatoid arthritis?

Authors:  James R O'Dell
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

3.  Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.

Authors:  Theodore Pincus; Ingrid Amara; Gary G Koch
Journal:  Arthritis Rheum       Date:  2005-04

4.  Trials: the next 50 years. Large scale randomised evidence of moderate benefits.

Authors:  R Peto; C Baigent
Journal:  BMJ       Date:  1998-10-31

5.  Summing up evidence: one answer is not always enough.

Authors:  J Lau; J P Ioannidis; C H Schmid
Journal:  Lancet       Date:  1998-01-10       Impact factor: 79.321

6.  Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.

Authors:  B Combe; C Codreanu; U Fiocco; M Gaubitz; P P Geusens; T K Kvien; K Pavelka; P N Sambrook; J S Smolen; J Wajdula; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

7.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

8.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

9.  Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.

Authors:  P L C M van Riel; A J Taggart; J Sany; M Gaubitz; H W Nab; R Pedersen; B Freundlich; D MacPeek
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

10.  Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.

Authors:  Jennifer J Anderson; James A Bolognese; David T Felson
Journal:  Arthritis Rheum       Date:  2003-11
View more
  2 in total

1.  Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial.

Authors:  Sarah Brien; Laurie Lachance; Phil Prescott; Clare McDermott; George Lewith
Journal:  Rheumatology (Oxford)       Date:  2010-11-13       Impact factor: 7.580

2.  Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.

Authors:  Saralynn Allaire; Frederick Wolfe; Jingbo Niu; Yuqing Zhang; Bin Zhang; Michael LaValley
Journal:  Arthritis Rheum       Date:  2008-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.